Inovio Pharmaceu Stock Price, News & Analysis

INOVIO (NASDAQ: INO) will release its fourth quarter and year-end 2020 financial results on March 1, 2021, after market close. A conference call and webcast will follow at 4:30 p.m. ET to discuss these results and provide updates on the company's DNA Medicines Platform, particularly its COVID-19 vaccine development. INOVIO, a pioneer in DNA medicines, is advancing clinical trials for its lead candidate VGX-3100, which targets precancerous cervical dysplasia linked to high-risk HPV types 16 and 18.

INOVIO Pharmaceuticals (Nasdaq: INO) has successfully closed its underwritten public offering of 20,355,000 shares at $8.50 each, generating approximately $173 million in gross proceeds. This includes an additional 2,655,000 shares purchased due to the underwriters' full exercise of their option. The offering was executed under an automatically effective shelf registration statement filed with the SEC on January 20, 2021. Funds from this offering are expected to enhance INOVIO's capabilities in developing DNA medicines for infectious diseases and cancer.

INOVIO Pharmaceuticals (Nasdaq: INO) announced the pricing of an underwritten public offering of 17.7 million shares of common stock at $8.50 per share, expected to yield approximately $150.5 million in gross proceeds. The offering includes an option for underwriters to purchase an additional 2.655 million shares. Proceeds will support clinical development, including INO-4800, and general corporate purposes. The offering is anticipated to close on January 25, 2021, following customary conditions. This offering was registered with the SEC and aims to advance INOVIO's DNA medicine pipeline.

INOVIO Pharmaceuticals announced a public offering of $150 million in common stock, with plans to grant underwriters a 30-day option for an additional 15%. Proceeds will fund clinical development, specifically for INO-4800, and cover general corporate expenses. BofA Securities, Jefferies, and Cantor are managing the offering. This follows their shelf registration statement filed with the SEC, effective January 20, 2021. The offering is subject to market conditions, and there are no guarantees regarding its completion.

INOVIO (NASDAQ: INO) announced promising results from a Phase 2 trial of VGX-3100 for HPV-16/18-associated vulvar dysplasia. At six months post-treatment, 63% of participants showed a clinically significant reduction in lesions, a stark contrast to the typical 2% spontaneous resolution rate. Notably, 15% of participants had resolved lesions with no detectable virus. The trial confirmed VGX-3100's safety, with no severe adverse events reported. INOVIO plans to advance to Phase 3 development based on these results, representing a potential breakthrough in non-surgical treatment options.

INOVIO (NASDAQ: INO) announces a collaboration with Advaccine Biopharmaceuticals to commercialize its COVID-19 DNA vaccine candidate INO-4800 in Greater China, including Mainland China, Hong Kong, Macao, and Taiwan. Advaccine will exclusively develop, manufacture, and market INO-4800 for an upfront payment of $3 million and potential milestone payments totalling $108 million. INOVIO will receive royalties on annual net sales. The collaboration leverages Advaccine’s manufacturing capabilities and clinical data to support INOVIO’s global regulatory filings while advancing the Phase 2 clinical trial of INO-4800 in China, involving 640 subjects.

INOVIO (NASDAQ: INO) has published peer-reviewed Phase 1 clinical data for its COVID-19 DNA vaccine candidate, INO-4800, in EClinicalMedicine. The study involved 40 healthy adults and demonstrated that INO-4800 generated an immune response in all participants with favorable safety, showing only six minor adverse events. The vaccine maintains stability at room temperature over a year, aiding global distribution. INOVIO is advancing to Phase 2 trials, funded by the U.S. Department of Defense, further validating the vaccine's safety and efficacy in upcoming segments.

INOVIO (NASDAQ: INO) announced a $37.6 million grant from DARPA to develop DNA-encoded monoclonal antibodies (dMAbs) targeting SARS-CoV-2. This funding will complement INOVIO's ongoing INO-4800 vaccine trial, enhancing treatment options for COVID-19. The dMAb technology offers rapid, cost-effective production of antibodies, overcoming limitations of traditional methods. The collaboration includes The Wistar Institute and AstraZeneca, aiming to advance dMAb candidates into preclinical studies and human trials within a year.

INOVIO (NASDAQ: INO) and Advaccine Biopharmaceuticals have initiated the Phase 2 clinical trial for INO-4800, a DNA vaccine candidate against COVID-19, in China. The trial, which is independent of the ongoing U.S. trial, aims to enroll 640 participants aged 18 and older, focusing on safety and immunogenicity. Dr. Joseph Kim, INOVIO's CEO, emphasized the collaboration's significance in accelerating vaccine development. The trial will consist of two doses at varying levels, providing critical data to support further evaluations of INO-4800.